Analysts see opportunity as Teva shares drop
July 25th, 2010 | by admin |Analysts see opportunity as Teva shares drop
Barclays Capital: Copaxone is significantly more difficult to characterize than Lovenox.
Read more on Globes Online
Related Blogs
- Seed Capital From Angel Investors: Alan Rossiter, Vice Chairman …
- When to Use Nofollow Links and Other SEO Onpage Optimization …
- The Pharmaceutical Giant TEVA Goes Downhill in the Stock Market …
- <a rel="nofollow" target="_blank"… | Freebies | Digital Scrapbooking
- <a rel="nofollow" target="_blank"… | Freebies | Digital Scrapbooking